Ohr Pharmaceutical to Present at Biotech Showcase(TM) 2012 in San Francisco on January 9
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 01/05/12 -- Ohr Pharmaceutical Inc. (OTCBB: OHRP) announced today that Dr. Irach B. Taraporewala, President and Chief Executive Officer, will present a corporate overview at the Biotech Showcase™ 2012 in San Francisco, CA on Monday, January 9, 2012 at 4:30 p.m. PT (7:30 p.m. ET). Dr. Taraporewala's presentation will include an overview of Ohr's clinical wet-AMD eye drop and cancer cachexia programs along with the Company's business outlook and expected milestones for 2012.
Ohr Pharmaceutical Inc. (OTCBB: OHRP) () is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The company is focused on two lead compounds: Squalamine eye drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia, currently being investigated in a Phase II trial.
Now in its fourth year, Biotech Showcase will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®. Public and private investors are invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry. Visit our website for more information: .
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.
Ohr Pharmaceutical Inc.
Sam Backenroth
Vice President, Business Development
212-682-8452
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.01.2012 - 13:40 Uhr
Sprache: Deutsch
News-ID 101395
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 163 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ohr Pharmaceutical to Present at Biotech Showcase(TM) 2012 in San Francisco on January 9"
steht unter der journalistisch-redaktionellen Verantwortung von
Ohr Pharmaceutical Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
